Skip to main content
. Author manuscript; available in PMC: 2011 Dec 15.
Published in final edited form as: Biochem Pharmacol. 2010 Jul 21;80(12):1833–1843. doi: 10.1016/j.bcp.2010.07.021

Table 4.

Active targeting of nanoparticle therapeutics in preclinical and clinical trials

Formulation Manufacturer Disease indications
PEG-anti-TNFα antibody fragment Nektar Crohn's desease, Rheumatoid arthritis
Rhenium-labeled doxorubicin Azaya Therapeutics Metastatic breast cancer
Methotrexate-folic acid Ployamidomine (PAMAM) dendrimers Michigan Nanotechnology Institute, University of Michigan Epithelial cancers
PEGylated hyaluronidase Halozyme Therapeutics Solid tumors
Prostate specific membrane antigen (PSMA) dendrimers BIND Biosciences Prostate cancer
Transferrin-diphtheria toxin conjugate Xenova (KS Biomedix) High-grade glioma